Finerenone Benefits T2D Across Spectrum of Renal Function :

Finerenone treatment of people with type 2 diabetes and albuminuria improved outcomes compared with placebo regardless of renal functional status.

Related Keywords

United States , Athens , Attikír , Greece , Stockholm , Sweden , American , Gerasimos Filippatos , Johann Bauersachs , Eli Lilly , Boehringer Ingelheim Lilly , Amgen , Karolinska Institute , Boehringer Ingelheim , American Diabetes Association , Novartis , Pfizer , Astrazeneca , Abiomed , European Society Of Cardiology , European Association For The Study Of Diabetes , Attikon University Hospital , Drug Administration , American Association Of Clinical Endocrinologists , Hannover Germany Medical School , Medtronic , Duke University , Novo Nordisk , European Society , European Association , New Reason , American Association , Clinical Endocrinologists , Consensus Report , Lars Ryd , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Diabetes , Diabetes Mellitus , Heart Failure , Chronic Renal Failure , Hronic Kidney Failure , Hronic Kidney Disease Ckd , Chronic Kidney Disease , Kd , Epidermal Growth Factor Receptor , Egfr , Genomics , Genomic Medicine , Edicine Genomic , Renal Failure , Enal Insufficiency , Idney Insufficiency , Kidney Failure , Clinical Guidelines , Uide ,